Reading time: 2 Min.
What is this about?
- You get the core debate: implant surface as a biologic interface, not a “rough vs. smooth” marketing point
- You see why “primary stability obsession” can backfire, especially in cortical bone and extraction sockets
- You learn how SLActive® is framed as a practical risk-reducer for immediate and regenerative indications
Implant surface is the real conversation, not just texture
In this Straumann® ProTalk “Clinical Edition” Episode, Professor Shakeel Shaddad frames implant therapy as placing a foreign body and then managing a biologic race: osseointegration versus fibrous encapsulation. He describes the “surface debate” as the interaction among blood cells, bone cells, and the implant surface, because the early clot and cellular response drive whether stability transitions successfully from primary to secondary. He links today’s expanded indications (immediacy, deficient sites, demanding GBR) to better tools – surface, design, and biomaterials – while reminding that patients want a tooth, not a specific surface, diameter, or suture.
SLActive® matters most in the first weeks, when the race is decided
Shaddad positions Straumann SLActive® as valuable not because it increases primary stability, but because it accelerates early biologic integration when primary stability naturally declines and the case is exposed to risk beyond the clinician’s control. He uses immediate implants in extraction sockets as an example: much of the implant surface is not in direct bone contact (especially facially), so the clinician relies on limited apical engagement while grafting the gap, making the early “handoff” to secondary stability critical. He explains the 20-year “turning point” as shifting the conversation from “long-term stability eventually arrives” to “how quickly can early stability become biologic stability,” using the sprinter-versus-marathon analogy to emphasize early speed rather than ultimate capacity.
Torque is not a trophy: compression can create the very bone loss you fear
A central theme is that insertion torque fixation becomes counterproductive: over-compression can increase osteoclastic activity, reduce vascular response, and trigger crestal changes—especially in cortical, thin bone. Shaddad argues for protecting implants from macro-motion rather than chasing extreme torque numbers, and he describes a clinical mindset where prosthetically driven placement stays “sacrosanct,” even if the implant initially feels like a “floater,” as long as the site is managed correctly (submerged healing, stability protection, and biologically favorable conditions). He also connects newer research directions to the “what’s next” question: not all hydrophilic surfaces behave the same, and patient-specific immune responses may become a future lever in understanding why some surfaces appear more pro-healing and less pro-inflammatory.
Key takeaways
- Implant success is framed as winning an early biologic race, not merely achieving a high initial torque
- Straumann SLActive® is positioned as an early-phase accelerator that supports immediate and regenerative workflows
- “Gentle with cortical bone” becomes a clinical principle: avoid crushing the crestal zone and prioritize controlled healing
The Straumann ProTalk hosts
Andreas Utz: Global Head of Business Unit Implantology at Straumann Group. A leading expert in implant dentistry, Andreas brings a wealth of knowledge and a passion for innovation to the podcast.
Dr. George Raeber: Global Head of Research & Development and Innovation at Straumann Group. With his extensive experience in the dental industry, George offers unique insights and thought-provoking perspectives.
